11. Myasthenia gravis Clinical trials / Disease details

Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04101578 (ClinicalTrials.gov)	February 8, 2017	16/9/2019	Clinical Prognosis and Progression of Myasthenia Gravis Patients	Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients	Myasthenia Gravis	Drug: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)	Da, Yuwei, M.D.	NULL	Recruiting	15 Years	N/A	All	2000		China
2	JPRN-UMIN000015019	2014/09/02	02/09/2014	Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG	Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG - Combined therapy for tacrolimus and IVIG	Myasthenia gravis	Tacrolimus and IVIG	Kansai medical university	NULL	Recruiting	Not applicable	Not applicable	Male and Female	20	Not applicable	Japan
3	NCT01179893 (ClinicalTrials.gov)	March 2007	9/8/2010	Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis	A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis	Myasthenia Gravid	Biological: IVIG;Procedure: PLEX	University Health Network, Toronto	Grifols Therapeutics Inc.	Completed	18 Years	N/A	Both	87	Phase 4	Canada
4	NCT00306033 (ClinicalTrials.gov)	March 2004	21/3/2006	Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis	IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial	Myasthenia Gravis	Drug: Intravenous ImmuneGlobulin	University Health Network, Toronto	NULL	Completed	18 Years	N/A	Both	50	Phase 3	Canada